Cincinnati Children's Hospital Treated Brain Tumor

A five-year-old patient recovered from a rare tumor following surgery and targeted molecular therapy.

Updated on Sept. 30, 2026 in Cancer

Cincinnati Children's Hospital Treated Brain Tumor

Doctors at Cincinnati Children's Hospital treated a five-year-old patient, Xander Shanahan, for a brain tumor that caused obstructive hydrocephalus. The child successfully recovered following surgery and a regimen of targeted molecular therapy.

Why it matters

The case highlights the growing role of genetic tumor testing in guiding personalized treatment plans for pediatric oncology patients. By identifying specific molecular characteristics, physicians can utilize targeted therapies to improve outcomes in complex brain tumor cases.

The patient, who first exhibited symptoms at age three, currently maintains his recovery while taking two daily oral medications. Genetic testing on the tumor was essential to facilitate the patient's significant tumor reduction.

The players

Cincinnati Children's Hospital

This is a prominent pediatric academic medical center in Cincinnati recognized for its research and specialized clinical care programs.

Xander Shanahan

He is a five-year-old patient who successfully recovered from a brain tumor after receiving surgery and molecularly guided therapy.

The details

After experiencing symptoms such as persistent vomiting, excessive sleeping, and eye misalignment, the patient underwent surgery to address the mass. The medical team at Cincinnati Children's Hospital supplemented the oral therapy with an integrated support plan including physical, occupational, and endocrinology services.

September 2026 marks the Childhood Cancer Awareness Month observation during which this case was highlighted.

The Big Picture

This case follows the clinical protocols and research patterns set by the Precision Oncology Initiative at Cincinnati Children's Hospital. By shifting from broad-spectrum treatments to molecularly targeted strategies, the institution is defining new standards for pediatric neuro-oncology.

This approach underscores the importance of seeking comprehensive genetic testing when evaluating pediatric brain tumors to explore targeted therapy options. Parents and patients should consult with specialists regarding how molecular profiling may influence the selection of clinical trials or specific medications.

The takeaway

Advancements in genomic medicine are increasingly allowing clinicians to tailor therapeutic responses to an individual's specific tumor profile. Families dealing with pediatric diagnoses should inquire about the availability of molecular tumor testing to ensure all potential treatment pathways are considered.